CROI 2024 included a wealth of studies on longer-acting pipeline compounds that could lead to new HIV drugs, many in novel combinations and using only two drugs.
HIV i-Base provided a comprehensive overview of the studies of new combinations that include either at least one investigational drug or a significant new indication. At least six studies included new clinical data on lenacapavir and numerous others looked at related issues including important early data on capsid inhibitor drug resistance.
Access the overview here.
Check out the dedicated page of the EATG site with the major highlights from CROI 2024.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.